| |
Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection
|
| |
| |
Brief Summary:
The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.
https://clinicaltrials.gov/ct2/show/NCT03847376
Contacts<
Contact: Contact 1-800-JANSSEN (1-800-526-7736) Janssenmedinfo"at"its.jnj.com
Sponsors and Collaborators
Janssen Sciences Ireland UC
ViiV Healthcare
Investigators
Study Director: Janssen Sciences Ireland UC Clinical Trial Janssen Sciences Ireland UC
|
|
| |
| |
|
|
|
